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Abstract 
Due to frequent clinical trial failures and consequently fewer new drug approvals, the need 
for improvement in drug development has, to a certain extent, been met using model-based drug 
development. Pharmacometrics is a part of pharmacology that quantifies drug behaviour, 
treatment response and disease progression based on different models (pharmacokinetic - PK, 
pharmacodynamic - PD, PK/PD models, etc.) and simulations. Regulatory bodies (European 
Medicines Agency, Food and Drug Administration) encourage the use of modelling and 
simulations to facilitate decision-making throughout all drug development phases. Moreover, the 
identification of factors that contribute to variability provides a basis for dose individualisation in 
routine clinical practice. This review summarises current knowledge regarding the application of 
pharmacometrics in drug development and clinical practice with emphasis on the population 
modelling approach. 
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Drug development encompasses a series of activities which include choosing a drug 
candidate among many potential compounds, preclinical and clinical research followed 
by the approval of the final product for marketing by the corresponding regulatory bodies 
and post-marketing surveillance (Figure 1) (1, 2). The goal of clinical trials is to obtain 
the clinical data to enable product labelling, which ultimately provides information to 
healthcare professionals and patients regarding drug efficacy and safety (1). The common 
path of clinical trials includes four phases: phase I – safety, tolerability and clinical 
pharmacology to support the trial; phase IIa – preliminary safety and efficacy; phase IIb 
– confirmation of efficacy and dose range finding; phase III – large scale confirmation of 
efficacy and safety aiming to support registration; phase IV – obligatory post-marketing 
surveillance (1). The greatest challenge in “first-in-human” studies is to determine the 
dose to be given, as well as the dosage form. Phase II studies have the lowest success rate 
out of all drug development phases and since they are exploratory in their nature, the 
obtained data could be misused in clinical practice (3). Since rare adverse reactions cannot 
be detected in phase III due to limited statistical power, duration of the trial phase and 
number of patients, the final phase IV further investigates treatment safety on a larger 
number of patients over a longer period of time and confirms the efficacy using clinical 
endpoints by performing mortality/morbidity and epidemiological studies (3, 4). 
 
 
Figure 1.  Drug development stages 
Slika 1.  Faze razvoja leka 
 
More frequent late phase failures, fewer approvals of new drugs, expiring patents 
and stricter price control from financiers lead to problems in research and development 
of new products (5). The main causes of clinical trial failures are considered to be: 




population, partial knowledge regarding the drug and indication of interest due to 
inadequate data collection, suboptimal determination of the primary endpoints, data 
analysis and interpretation (6). 
Therefore, model-based drug development (MBDD) has been suggested to improve 
the success rate of new drug development and clinical trials in general. This approach 
provides better insight into the drug candidate behaviour and ensures facilitated decision-
making (5). Food and Drug Administration (FDA) has established the "Critical Path 
Initiative," a document which suggested the usage of a MBDD, where pharmacometrics 
is believed to play a critical role (7). Indeed, many articles confirm the importance of 
using pharmacometric analysis in more informed regulatory decisions (8-11). In addition, 
several regulatory guidelines and documents have been issued (12-16). 
Pharmacometrics is applied to quantify drug, disease and trial characteristics to 
support not only drug development and regulatory decisions, but also rational drug 
treatment (10, 17). Hence, this review aims to provide an overview of the application of 
pharmacometric analysis, focusing on the drug model and population approach. More 
information about disease progression and trial models may be found elsewhere (18). In 
the first section, commonly used pharmacokinetic (PK), pharmacodynamic (PD) and 
pharmacokinetic/pharmacodynamic (PK/PD) models will be introduced, followed by the 
concept of population modelling approach, frequently used software packages, and a brief 
overview of the main steps in the population model development and simulations. In the 
following sections, the role of pharmacometrics in drug development and clinical practice 
will be presented, focusing on population modelling and simulations. The final section 
presents the role of population modelling in special population. 
Pharmacometric analysis approach 
Pharmacometrics uses mathematical models based on pharmacology, physiology 
and disease to describe and quantify interactions between drugs and patients (19-21). It 
is primarily based on modelling and simulation of data, which includes, but is not limited 
to, PK, PD, and PK/PD modelling with a focus on population and variability (21, 22). 
Pharmacometrics is an evolving science that continuously improves and encompasses or 
connects other disciplines. Methodologies such as the physiologically-based 
pharmacokinetic (PBPK) modelling approach and quantitative systems pharmacology 
have recently gained much broader applications in drug development (21).  
Type of PK and PK/PD models 
PK models describe how drug concentration in the body changes over time. 
Compartmental modelling is the most frequently used approach, in which the body is 
represented as a system of connected but separate compartments. A compartment is a 
group of tissues or organs with a similar blood flow and affinity for the drug. Models 
usually include a central compartment representing where the concentration is measured 
(e.g., plasma), with one or more peripheral compartments into which drugs may distribute 




descriptions of the observed data, without such mechanistic elements (21, 23). Combining 
the classical compartment model and statistical principles led to the development of the 
population PK modelling analysis.  
PD models describe the relationship between drug concentrations and drug effect. 
PK/PD models link dose and PK information to certain measures of activity and clinical 
outcomes. Beside treatment efficacy assessment, drug safety profile may be characterised 
as well (21, 24, 25). Common concentration-effect models for continuous PD metrics 
include linear, log-linear, maximum effect (Emax), and sigmoidal Emax models (21, 24-26). 
An example of the relationship between PK and PD is presented at Figure 2 (23, 26). 
Drug concentration in the central compartment may be directly linked to the effect (direct 
effect), or there may be a time delay due to a biophase equilibration (effect compartment 
model) or the need to develop a response (indirect response model) (21, 25, 26). 
Moreover, transit compartment models and the development of tolerance may be included 
(21, 25). Models describing discrete PD effects usually use logistic equations to convert 
the effect to a probability (21, 24, 25), or time to event analysis including single or 
multiple events (27).  
 
 
Figure 2.  Pharmacokinetic (PK), pharmacodynamic (PD) and PKPD models 







Population pharmacometric analysis methodology 
Population PK can be defined as a study of variability in drug concentrations among 
individuals (12, 28). Over the past few decades, a variety of modelling methods have been 
proposed (29, 30). The concept of population PK, based on non-linear mixed effects 
(NLME) approach, was introduced in 1972 by Sheiner et al. (31). NLME involves the 
simultaneous estimation of the typical and variance parameters using data of the entire 
population (30). Initially developed to analyse sparse PK data, this approach was later 
expanded to include PD models (24). Nowadays, this methodology represents a golden 
standard for population analysis, and the terms are often used as synonyms (24, 30). It is 
widely used because of the ability to quantify several variability levels, handle sparse, 
unbalanced and fragmentary data, and identify influential covariates (14, 24, 30, 32-34). 
Hence, available software and modelling aspects of NLME are described in more details 
in the following text. 
NONMEM was the first software package developed for population modelling 
analysis, realised in the early 1980s (35). Subsequently, other software packages have 
been developed, such as Monolix (36), Phoenix NLME (37), various packages in R (38), 
and many more. Most of the software applies parametric maximum likelihood estimation, 
but other approaches are also available (39). 
The development of a population PK or PK/PD model includes several steps 
defined in the pharmacometric analysis plan (12, 21, 40, 41). To better understand the 
data and guide model development, exploratory analysis is recommended, including 
various graphical and numerical methods (21, 40, 41). 
In the initial step, the structural and statistical model ought to be developed. The 
structural model describes the PK and PD characteristics for a typical subject (e.g. one-
compartment with lag time, or sigmoidal Emax model) (21, 24, 25, 33). Fixed-effect 
parameters are structural parameters that describe drug behaviour in a typical subject. 
Certain covariates may be included as a part of this base model only if a good rationale 
exists (40, 41). Statistical (stochastic) models describe the unexplained variability 
(random effects) in the observed data (24, 25, 42).  In contrast to the classical approach, 
population models may distinguish between-subject (variability of a parameter across 
individuals) and residual variability (the difference between the observed data and the 
model predictions). Models may also include, where relevant, between-occasional 
variability, usually observed in drugs used in oncology treatments (24, 25, 42, 43). The 
next step includes covariate model development aiming to explain the variability and 
describe the influence of intrinsic and extrinsic factors (covariates) on model parameters 
(24). Covariates are subject-specific factors such as demographics (body weight, age, 
gender, race), physiologic and pathophysiologic characteristics, biochemical laboratory 
parameters’ values, genetic polymorphism, co-medications, and environmental factors 
(e.g., smoking, alcohol intake) that may impact PK and/or PD variability (43). Among 
several methods in covariates evaluation (40, 41), stepwise covariate model (SCM) 




clinical relevance of candidate covariates should be considered. After assessing and 
retaining all the relevant covariates, model may be regarded as final (21, 40). 
Model diagnostics are performed during each of the key steps of the process, 
including the validation of the final model (40). Ultimately, the evaluation and 
qualification confirms the adequacy of data description by the model regarding its 
behaviour and proposed purpose (21). Among many diagnostic tools and validation 
techniques (34, 41, 42, 45, 46), the most appropriate one should be chosen depending on 
the type of data and the purpose of the model (descriptive or predictive) (12, 42, 47). In 
general, a combination of several methods is preferred so that the relative strengths and 
shortcomings of each approach can complement each other (14).  
Pharmacometric models could be used for simulation studies, where they could be 
useful for predicting different clinical scenarios not accounted for by the study design, 
such as different dosage regimens or other patient populations. Generally, stochastic 
simulations using a mixed effect model are more complex than non-stochastic simulations 
based on a model with fixed effects (21, 24). Depending on the purpose of the simulation, 
the variability and parameter uncertainty should be considered (14, 21). Finally, the 
results of any modelling and simulation analysis should be appropriately reported (12, 21, 
40, 41).  
Role of population pharmacometric approach in drug development 
Pharmacometrics can be used in every phase of drug development, from molecule 
screening to post-marketing surveillance. Both clinical and nonclinical decisions are 
made with the support of pharmacometrics: go/no-go decisions, dosage range, end points, 
trial timing, trial design development, etc (23). However, the population modelling 
approach is primarily used in clinical development, while its application in preclinical 
phase is still limited. Nevertheless, population analysis can be utilised in this stage to 
summarise the PK data and PK/PD relationships obtained from different animal groups 
or species, predict parameter values in humans, optimise subsequent trial designs, and 
reduce the time from new drug discovery to clinical trials (48-50). For instance, 
compartmental modelling in allometric scaling-up can be performed by population PK in 
addition to the classical approach (50).  
Clinical drug development 
Design inefficiencies, inadequate efficacy and safety outcomes, blood sampling 
schemes, and clinical trial failures can be avoided by incorporating disease drug trial 
models and clinical trial simulations (22, 51). Simulations can predict essential data 
regarding drug behaviour after repeated drug administration, potential drug interactions 
and their impact on PK/PD profiles, the influence of hepatic/renal failure, and the dose 
required to achieve target concentration. They can also be useful in estimating the sample 
size and choosing the adequate statistical test to obtain the greatest power (52). The 
success rate of clinical trials is improved by studying the impact of protocol deviations, 




The rationale for using modelling in phase I of clinical trials lies in the possibility 
of estimating PK and PD parameters of the population, dosage regimen optimisation, 
selection of the most efficacious sampling and combined data analysis (24, 54). 
Subsequent clinical trial phases incorporate population models in order to characterise 
therapeutic index, food effects, drug-drug and drug-disease interactions, exposure-
response relationship, clinical and patient variability factors, benefit-risk ratio and 
contribute to various regulatory decisions (22, 23, 55). Before each new clinical trial 
phase, design optimisation is performed by simulating possible outcomes and analysing 
the available data. In the final pre-approval stage of clinical development, modelling and 
simulation can offer additional recommendations regarding patient-specific dose 
adjustment, new indications, bridging studies and post-marketing study design. Selecting 
the best possible biomarker and its target value for optimal response is one of the critical 
assignments of this approach. Even the drug effect parameter of a PK/PD model has been 
suggested as a good substitution for clinical trial endpoint (56).  
The abbreviated approval pathway for biosimilars differs from the pathway for 
generic drugs. Population modelling is used to acquire the doses for PK and PK/PD 
similarity studies, improve the design of the study based on interindividual variability, 
verify PD biomarkers and compare different administration routes to approve new 
formulations (57). Model-based simulations are convenient to demonstrate the dose-
exposure relationship of drugs with nonlinear PK, which is common among biologic 
drugs, mostly due to target-mediated drug disposition (58). 
Regulatory aspects  
With a growing interest in pharmacometrics, the need for the development of 
appropriate guidelines has been recognised by regulatory agencies. The European 
medicines agency (EMA) and FDA provide guidance files on the use of on population 
PK analyses (12, 14). While EMA shifts the focus of the guidance file to analysis plan 
and more detailed information regarding result report, FDA provides methodological 
aspects and information about data used for population PK analysis. Additionally, EMA 
has issued guidelines for different special populations on the role of PK in the 
development of medicinal products. The guideline for the paediatric population 
summarises the use of PK and PK/PD relationships in efficacy and safety evaluations, 
study design and data analysis, suggesting population PK analysis as an appropriate 
methodology for practical and ethical reasons (59). Moreover, the FDA guideline for 
exposure-response relationship highlights the usefulness of population PK analysis 
combined with the Bayesian method when analysing sparse data, which is often the case 
in paediatric or geriatric populations (16). The goal of these regulatory initiatives is to 
support the use of pharmacometrics throughout all drug development stages and 
encourage pharmaceutical industry to implement it in their research and development, 




Post-marketing research and application in routine clinical practice  
Post-marketing research and lifecycle management 
The main goal of phase IV or post-marketing surveillance studies is to verify the 
effectiveness and safety of the drug in a real life conditions (60). Contrary to the pre-
marketing trials, these studies include a larger number of patients and more heterogeneous 
population in the terms of age, gender, comorbidities, concomitant therapy and genotype 
(61). Such clinical trial settings, empowered by the population approach methodology in 
data analysis, enable the identification of factors not detected in the previous phases of 
the clinical trial that contribute significantly to variability in drug exposure and response 
(23). Thus, relevant information about drug-drug interactions, drug-disease interactions 
and the influence of other factors can be characterised in real life conditions (23). 
Furthermore, the population PK approach is useful when analysing sparse data, which is 
often the case in routine clinical practise and during therapeutic drug monitoring (TDM). 
For instance, numerous population PK models for antiepileptic drugs were created, even 
though the number of blood samples was limited (62-66). Similarly, the utility of 
population PK approach could be observed in characterising immunosuppressive drugs’ 
PK. Golubovic et al. developed population PK models based on TDM data of sirolimus 
and tacrolimus from adult kidney transplant patients (67, 68). Moreover, the published 
population models and intrinsic and extrinsic factors contributing to variability for 
specific therapeutic groups are summarised in review articles (69, 70).  
Additionally, the advantages of modelling are reflected in its ability to integrate 
data from different stages of drug development - preclinical, clinical and post-marketing 
surveillance studies, which facilitates further investigations of the drug PK and PD in 
different populations of patients (23). Furthermore, population PK analysis facilitates the 
determination of dosing regimen for some off-label drugs (56) and new formulation 
development (23). 
Dose individualisation 
Besides having a substantial role in drug research and development, 
pharmacometrics has an increasing impact on routine clinical practice in healthcare 
systems. In the centre of each healthcare system is a patient with his/her specific, 
individual characteristics to whom a drug, in a certain dosage regimen, is prescribed. 
Usually, the dose prescribed is the same for every patient (71). However, for some drugs, 
the response to the usual dosage regimen is often different between patients and 
sometimes can even vary within the individual patient. Such an unexpected response to 
drug therapy can result in treatment failure. These consequences are reflected in disease 
progression and/or occurrence of adverse effects, which leads to decreased quality of life 
in patients and additional expenses of health-care systems (72, 73). Therefore, identifying 
and quantifying the sources of PK and/or PD variability is the cornerstone of therapy 
individualisation (74, 75). Although TDM is one of the oldest tools used to optimise 




when it comes to dosing optimisation recommendations. The main flaw of traditional 
TDM is the existence of a reference range of concentrations instead of one target 
concentration, which means that a clinician's decision making is driven by experience, 
rather than evidence-based facts (71, 76). Moreover, samples should be taken from 
patients after steady state is achieved (77). One way to overcome the disadvantages of 
classical TDM is to use approaches that take into account the drug, disease, and patient 
characteristics, such as the model informed drug precision approach (MIPD) (78). In this 
approach, TDM data, together with the individual patient’s demographic, 
pharmacogenetic, clinical and therapy characteristics, are interpreted using the population 
model (31, 77, 79). Even before the administration of the first dose, the developed model 
can be used to calculate population parameters considering covariates for the specific 
patient and propose dosage regimen based on these estimates. When measured drug 
concentrations become available, the patient’s parameters can be estimated through so-
called Bayesian forecasting (80). It uses prior information about population model 
parameters and their uncertainties together with measured drug concentrations and 
individual covariates to maximize the probability of individual parameter values 
(maximum a posteriori Bayesian estimate). Consequently, the estimated individual 
parameters are further used for more precise dosage regimen optimisation (56, 77, 81). 
Moreover, simulations can be performed based on the individual PK parameters, to obtain 
a dosing regimen that maximizes the achievement of the target (77). Due to the 
complexity of NONMEM software in routine clinical practice, new tools are being 
developed (82). Currently, around 28 software tools based on MIPD are available for 
research and/or clinical purposes, and approximately half are using the Bayesian approach 
(83). At the moment, the majority of the software is intended for optimal dose selection 
for antibiotics, as appropriate dosing is essential from the beginning of the therapy (78, 
80, 83). A confirmation of the utility of MIPD in dose selection and optimisation has 
recently been published in the Consensus guidelines on TDM of vancomycin. The 
guideline suggests that Bayesian based software programs are a preferable tool for dosing 
regimen creation/adjustment in order to achieve the target value of area under the curve 
(84). However, regardless of the numerous advantages of Bayesian-based software 
programs, some challenges need to be resolved before their implementation in routine 
clinical practice (80, 82). Another tool for dosing individualisation that can be used 
together with the PK/PD models or Bayesian approach is target concentration 
intervention. Its use requires target concentration/biomarker and estimated values of key 
PK and/or PD parameters for the calculation of loading and maintenance dose. After the 
calculated doses are given to the patient, the drug concentration or response is measured 
again and used as feedback in the decision making process (71, 76). 
Special populations 
Patients younger than 18 years (paediatrics), older than 65 years (elderly), women 
(pregnant or non-pregnant), or patients with certain diseases (kidney/liver 




special populations (85, 86). Usually, these patients are excluded from clinical trials due 
to their vulnerability, ethical reasons, and strict regulation laws (85, 87). Nevertheless, a 
practitioner needs to prescribe a drug in an appropriate dosing regimen to these patients, 
having in mind the factors that differentiate special population patients from the general 
population of adults. Using identical dosing regimens in patients that belong to a special 
population can result in either a lack of drug efficacy, or drug toxicity, as a consequence 
of changed physiology (pathophysiology), and consequently the drug’s behaviour (85, 
87). 
Including special populations in clinical trials requires certain modifications of the 
typical study design. The most apparent one is a limited number of participants and sparse 
data sampling, which could be adequately handled only by the modelling and simulation 
approaches (87, 88). Hence, dosing recommendations for special populations may be 
obtained, and sometimes simulation studies can even substitute clinical trials in the 
mentioned groups (14, 23). Children go through developmental changes in terms of body 
size/body composition and organ function (89), which is especially important in infants 
(90). The influence of developmental changes can be assessed by using size and/or age 
as covariates in population analysis (32, 91). One approach used to describe midazolam 
clearance in critically ill children is based on allometric scaling combined with sigmoidal 
maturation function (92). On the other hand, in older critically ill patients, the reduction 
of elimination organ function should be accounted for. Hence, the developed population 
model of vancomycin explains the impact of creatinine clearance on drug elimination, 
indicating that renal function should be considered for dosing regimen optimisation (93).  
The possibility of predicting the optimal dosing regimen in vulnerable populations 
in order to achieve target exposure can be seen in study by Wallender et al. (94), where 
the authors proposed an alternative dosage regimen of an antimalaric drug for pregnant, 
HIV infected women ensuring safe and effective prophylaxis. 
Finally, the application of PBPK modelling approach has been continuously 
increasing over the past several years (95). PBPK models use population-specific 
physiologic parameters, drug-specific physicochemical and PK information as input 
parameters in modelling process, in order to predict drug disposition in various 
populations (96, 97). Considering the mechanistic nature and the possibility of integrating 
population-specific physiologic changes, PBPK may be useful for a variety of purposes 
in specific populations and especially in assessing drug-drug interactions (95, 97). 
Regarding children younger than 2 years, it has been even debated whether this approach 
may be preferred over allometric-scaling (95). In general, the use of PBPK models in drug 
development is supported in regulatory documents (98-100). 
Conclusion 
Population analysis, as an integral part of pharmacometrics, has a wide range of 
applications in drug development and direct patient care. The process of model 
development and evaluation depends on the purpose of the model. Population analysis 




population analysis allows simulations that can be used to answer “what-if” questions. A 
special case of predictive population analysis is the utilisation of the developed model to 
design a future clinical trial. Finally, the identification of the influential covariates 
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Usled čestih neuspeha u kliničkim ispitivanjima i posledično manjeg broja odobrenja novih 
lekova, potreba za poboljšanjem u razvoju lekova je u određenoj meri zadovoljena korišćenjem 
pristupa razvoja lekova zasnovanog na modelu. Farmakometrija predstavlja granu farmakologije 
koja kvantifikuje ponašanje leka, odgovor na terapiju i napredovanje bolesti na osnovu različitih 
modela (farmakokinetički - FK, farmakodinamički - FD, FK/FD modeli itd.) i simulacija. 
Regulatorna tela (Evropska agencija za lekove, Uprava za hranu i lekove) podstiču primenu 
modelovanja i simulacija u svrhu lakšeg donošenja odluka tokom svih faza razvoja lekova. 
Štaviše, identifikacija faktora koji doprinose varijabilnosti predstavlja osnovu za individualizaciju 
doze u rutinskoj kliničkoj praksi. Ovaj revijalni rad sumira trenutno znanje u vezi sa primenom 
farmakometrije u razvoju lekova i kliničkoj praksi sa fokusom na populacionu analizu. 
 
Ključne reči: farmakometrija, populaciona analiza, farmakokinetika,  
   farmakokinetičko-farmakodinamičko modelovanje 
 
 
 
